KissPeptin-10 in Neuropeptide Research requires traceable specification (5mg / 10mg) and RUO acknowledgment; KissPeptin-10 Specification and Vial Format Review outlines buyer steps on sulanpeptide.vip.
KissPeptin-10 is a decapeptide fragment used in laboratory research on KISS1 receptor signaling, neuroendocrine pathway models, reproductive-axis signaling, and receptor-activation studies.
KissPeptin-10 activates KISS1R (GPR54), triggering Gq-mediated signaling and downstream GnRH release in hypothalamic neuron models. The decapeptide (KISS-10) represents the minimal active fragment studied in receptor pharmacology compared with KISS-54 isoforms.
KISS1R cAMP/IP3 assays, GnRH radioimmunoassay from hypothalamic explants, and puberty-onset timing models in rodents are core experimental formats. Seminal 2003 Nature genetics papers linked KISS1R mutations to hypogonadotropic hypogonadism, driving extensive kisspeptin probe development for neuroendocrine research.
Side-by-side review of specification table, vial label, and COA prevents release errors for KissPeptin-10. Principal investigators should sign off KissPeptin-10 SKUs only after mechanism fit is documented in the study protocol.
Spec alignment: Enter exact strength notation (5mg / 10mg) in procurement systems—do not round kit counts.
Catalog identifiers for KissPeptin-10: CAS 374675-21-5, Formula: C63H83N17O14. MW 1302.4 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for KissPeptin-10 to support reproducibility.
Dose planning for KissPeptin-10 should state mass (5mg / 10mg) or molarity derived from catalog molecular weight.
Format selection for KissPeptin-10 affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for KissPeptin-10. QA sign-off should reference all four documents in the batch record.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for KissPeptin-10 should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type. Specification alignment for KissPeptin-10 requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Molecular identifiers for KissPeptin-10—CAS 374675-21-5, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing KissPeptin-10 should include these fields for reproducibility in Neuropeptide Research journals.
Specification alignment for KissPeptin-10 requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits. Molecular identifiers for KissPeptin-10—CAS 374675-21-5, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing KissPeptin-10 should include these fields for reproducibility in Neuropeptide Research journals.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for KissPeptin-10 should state whether the lot COA must meet or exceed that threshold for your Neuropeptide Research assay type.
KissPeptin-10 from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.